Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
161
resultados
Última actualización
05/04/2026 [06:53:00]
Resultados 100 a 125 de 161
Resumen de: US20260083682A1
The present invention relates to a kit for construction of drug-containing nanoparticles and a nanoparticle composition for drug delivery. More specifically, the present invention concerns a kit for construction of drug-containing nanoparticles and a nanoparticle composition for drug delivery, each designed to increase the efficiency of cellular drug delivery by utilizing nanoparticles that include a cationic compound and an anionic polymer compound with at least one acidic functional group.
Resumen de: US20260083683A1
A protein nanospheres and method to treat dysfunction from chemotherapy and immunosuppressive therapy, and a manufacture of fibrinogen-coated albumin spheres (FAS) and High-Fibrinogen Spheres (HFS) which have higher concentrations of fibrinogen molecules per sphere than FAS, and their use for medical treatments. Both kinds of nanoparticles are effective in the mitigation of the toxic effects of certain chemotherapeutic and radiological agents that are typically used in the treatment of cancer, or the treatment of autoimmune diseases, or for patients with both diseases. FAS and HFS can exert their beneficial effects via a variety of mechanisms which match the need of the body for specific cell types, including any of the subgroups of T cells and antibody producing cells, the relative concentration of each kind is vital to the balance between tumor surveillance and autoimmune disease suppression.
Resumen de: US20260083769A1
The present disclosure provides delivery vehicle compositions comprising hydroxyalkyl-capped cationic peptoids, such as 2-aminopropane-1,3-diol-capped cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for the delivery polyanionic compounds (e.g., nucleic acids) to cells. The disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the disclosure.
Resumen de: US20260083680A1
A mesoporous nano-magnesium oxide for drug loading and a preparation method thereof are provided. The mesoporous nano-magnesium oxide particle has a particle size of 50 nm to 150 nm, and includes abundant mesoporous structures with a pore size of 2 nm to 20 nm. A surface of the particle has a positive potential in absolute ethanol, with a Zeta potential distribution of 10 mV to 100 mV. The preparation method includes: preparing a mixture of magnesium oxalate and CTAB as a precursor; adding the precursor to a quartz crucible, and placing the quartz crucible in a muffle furnace; calcining at 200°C for 1 h to make the CTAB in the mixture completely decomposed to produce pure magnesium oxalate; and heating to 530°C, and calcining for 1 h to 6 h to make the magnesium oxalate fully decomposed to produce the nano-magnesium oxide microparticle.
Resumen de: US20260083673A1
Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic/injured area).
Resumen de: US20260086085A1
Methods and systems for analyzing lipid nanoparticles using size exclusion chromatograph coupled with multi angle light scattering are disclosed.
Resumen de: US20260085120A1
Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Still also described are methods for treating and/or increasing the therapeutic effectiveness of an immunotherapy of a patient suffering from a cancer which expresses PD-LI or PD-L2 by administering to the patient a nanoparticle composition and a PD-I immunotherapy.
Resumen de: AU2026201779A1
Formulated and/or co-formulated liposomes comprising IDO prodrugs and methods of making the liposomes are disclosed herein. The IDO prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit IDO-1. The IDO prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle. ar a r
Resumen de: AU2024357274A1
The invention relates to lipid nanoparticles, immunogenic compositions and methods for use thereof.
Resumen de: AU2024345757A1
The present invention relates to oligoglycerol-containing lipids and in particular to cationic or cationizable oligoglycerol-containing lipids and to a method for providing these oligoglycerol-containing lipids. Further, the present invention relates to liposomes, in particular thermosensitive liposomes comprising the novel oligoglycerol-containing lipids. Further the invention relates to liposomes comprising the novel oligoglycerol-containing lipids, which liposomes have an adjustable surface charge.
Resumen de: AU2024332565A1
The present disclosure provides lipidoid compounds of formulae (I) and (II) and compositions comprising them, methods of preparing such compositions, and the use of these compositions in gene delivery applications.
Resumen de: AU2024325364A1
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use such as a compound of Formula (A) or a pharmaceutically acceptable salt thereof.
Resumen de: WO2026064512A1
The present disclosure provides novel polymer-conjugated lipids conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations, including multiple doses of the LNP formulations.
Resumen de: WO2026062291A1
The present invention belongs to the field of biomedicine and drug delivery. The invention relates to LipexSil® lipid-containing nanoparticle ("LNP") compositions, that permit preferential targeting of spleen versus liver, where preferential targeting is defined as a luminescence intensity ratio of spleen and liver greater than 9 after administration of a luminescent cargo, when the different weights of spleen and liver are taken into account. In the LNP composition, a silicon-containing ionizable lipid is combined with a certain structural lipid, a helper lipid, a shield lipid and a fifth lipid component. The invention describes the production and characterization of the lipid nanoparticles and in vivo experiments demonstrating that the corresponding formulations with LipexSil® lipids as described in WO2024/023174 are superior to the current approach, delivering their cargo (e.g. RNA, DNA, mRNA, microRNA, siRNA, ceDNA, pDNA, circular DNA, small biologically active molecules) preferentially to the spleen.
Resumen de: WO2026062193A1
A method of producing a composition containing a nucleic acid-lipid particle, the method comprising the steps (a) to (d): (a) preparing a first mixture which is a lipid mixture comprising a cationically ionizable lipid in a water-soluble organic solvent; (b) preparing a second mixture in aqueous solution, the second mixture comprising (i) a nucleic acid and (ii) malate buffer; (c) mixing the first mixture with the second mixture to produce an intermediate composition comprising the nucleic acid-lipid particle; and (d) further processing of the intermediate composition by buffer exchange, wherein the buffer used in the buffer exchange comprises tris(hydroxymethyl)-aminomethane (Tris) and/or a pharmaceutically acceptable salt thereof, to produce the composition comprising the nucleic acid-lipid particle; is provided.
Resumen de: WO2026061393A1
Provided in the present invention are a lipid nanoparticle used for delivering a nucleic acid molecule that encodes a secretory protein and the use thereof. The lipid nanoparticle can deliver the nucleic acid molecule to the liver for the treatment of liver diseases and other diseases. Also provided in the present invention are a preparation method for the lipid nanoparticle, a pharmaceutical composition comprising the lipid nanoparticle, and the use of the lipid nanoparticle and the pharmaceutical composition in the treatment of diseases.
Resumen de: WO2026064341A2
Disclosed are polymeric nanoparticles and microparticles having a tunable elastic modulus and having one or more biological proteins conjugated to a surface thereof and their use in immunotherapies for treating diseases, such as cancer or infectious diseases.
Resumen de: WO2026064396A1
Orally administrable nanoparticle complexes of biological molecules and biopolymers are described herein, and include formulations for the oral administration of peptides, proteins, nucleic acids, and antibodies.
Resumen de: WO2026061537A1
The present invention provides an ionizable lipid compound, and specifically relates to a compound of formula (I'), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof. The present invention also provides a nanoparticle pharmaceutical composition comprising the compound, and a use of the compound and the composition comprising same in nucleic acid delivery.
Resumen de: WO2026060590A1
The present application relates to the technical field of nanocapsules for medical preparations, and particularly relates to dTRIM24 biocompatibility-based anti-atherosclerotic nanoparticles composed of nanoparticles and M1 macrophage membrane vesicles. By using a microfluidic photoporation chip, the nanoparticles are encapsulated by the M1 macrophage membrane vesicles. The nanoparticles are obtained by combining dTRIM24 and Fe3O4 magnetic nanoparticles. The biomimetic nanoparticles of the present application reasonably solve the problems of poor specificity and low efficiency, and have improved anti-atherosclerotic plaque-targeting and biological homology.
Resumen de: WO2026060495A1
The present disclosure relates to ionisable lipids of Formula I and related structures that comprise a headgroup, core, and hydrophobic substituents. The lipids are capable of forming lipid particles, including lipid nanoparticles (LNPs), in combination with additional lipids such as neutral lipids, charged lipids, structural lipids, or PEGylated lipids. The lipid particles are suitable for delivery of therapeutic agents, including polynucleotides, peptides, antibodies, and small molecules. Compositions comprising the ionisable lipids and methods of forming and using the lipid particles are also provided.
Resumen de: WO2026060493A1
The present disclosure relates to ionisable lipids of Formula I and related structures that comprise a headgroup, core, and hydrophobic substituents. The lipids are capable of forming lipid particles, including lipid nanoparticles (LNPs), in combination with additional lipids such as neutral lipids, charged lipids, structural lipids, or PEGylated lipids. The lipid particles are suitable for delivery of therapeutic agents, including polynucleotides, peptides, antibodies, and small molecules. Compositions comprising the ionisable lipids and methods of forming and using the lipid particles are also provided.
Resumen de: AU2023452365A1
Present disclosure describes a lipid polymer hybrid nanoparticle and a method to synthesize such nanoparticles or such nanoparticle-containing compositions. The nanoparticles are made of biodegradable polymer based micellar core surrounded by lipid-based shell, wherein majority of a pharmaceutical agent is present on the inner periphery of such nanoparticles due to physical adherence with the lipid molecules. Only a minor amount of the pharmaceutical agent is encapsulated in the micellar core. Hence, the lipid-based shell becomes a primary excipient part of the nanoparticle and the biodegradable polymer containing core becomes a secondary excipient part of the nanoparticle.
Resumen de: WO2026064752A1
Disclosed are compositions and methods for in vivo genetic engineering of lymphocyte precursors. A lipid nanoparticle (LNP), surface-functionalized for lymphocyte precursor targeting, encapsulates a DNA payload comprising a therapeutic gene flanked by engineered Recombination Signal Sequences (RSS). The RSS spacer incorporates at least one non-natural nucleotide, reducing integration risks. Because RAG1 and RAG2 are expressed only after commitment to the lymphoid lineage, integration is restricted to immune precursors and cannot occur in stem cells or reproductive cells. Upon systemic delivery, the endogenous RAG1/RAG2 complex integrates the payload into the precursor genome. Modified precursors undergo clonal expansion in vivo, amplifying the therapeutic effect from relatively low doses. In certain embodiments, the DNA payload encodes receptors or antibodies that specifically recognize aggregated amyloid proteins, including transthyretin (TTR) fibrils and immunoglobulin light- chain aggregates, enabling therapeutic treatment of amyloidosis. However, the platform is not limited to amyloidosis and can be applied to oncology, infectious diseases, autoimmune disorders, and other protein misfolding conditions.
Nº publicación: WO2026064536A1 26/03/2026
Solicitante:
UNIV OF FLORIDA RESEARCH FOUNDATION INCORPORATED [US]
THE JOHNS HOPKINS UNIV [US]
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED,
THE JOHNS HOPKINS UNIVERSITY
Resumen de: WO2026064536A1
The disclosure provides a liposome nanoparticle, a pharmaceutical composition comprising liposome nanoparticles, and a method of treating brain cancer. In some aspects, the liposome nanoparticle comprising a folate bearing lipid and nucleic acid molecules (e.g., siRNA or shRNA) that reduce the expression of H2.0 Like Homeobox (HLX). The liposome nanoparticle optionally comprises a diameter of about 50 nm to about 400 nm. In some aspects, the pharmaceutical composition comprises the liposome nanoparticles and a pharmaceutically acceptable carrier, diluent, or excipient. In some aspects, the method of treating brain cancer comprises administering to a subject in need thereof the liposome nanoparticle.
BOPI
Sede Electrónica
